Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)
Pharmaceuticals, 18 (2), 214
Both in vivo and in vitro studies provide substantial evidence of the neuroprotective benefits of GLP-1RAs through the modulation of inflammation, mitochondrial function, ROS, tau hyperphosphorylation, and anti-apoptotic pathways
22 Mineralocorticoid receptor antagonists (MRA) have also demonstrated clinical benefit in patients with HFpEF
These results suggest that the follow-up duration of the study or diabetes status at baseline are not individual culprits behind the variation among the studies
Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF: Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents